{"disease":{"id":"post-transplant-cytomegalovirus-infection","name":"Post-transplant cytomegalovirus infection","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"maribavir","indication_name":"Post-transplant cytomegalovirus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livtencity","generic_name":"MARIBAVIR","company_name":"Takeda","drug_phase":"marketed","molecular_target":"","drug_class":"Cytomegalovirus pUL97 Kinase Inhibitor [EPC]","quality_score":65,"revenue":"300","mechanism":"Livtencity works by inhibiting the pUL97 kinase enzyme, which is essential for the replication of cytomegalovirus."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}